Savara Inc. presented additional analyses from its pivotal Phase 3 IMPALA-2 clinical trial of molgramostim in autoimmune pulmonary alveolar proteinosis (aPAP) at the European Respiratory Society (ERS) Congress 2025 in Amsterdam, The Netherlands. These presentations provided further insights into the drug's efficacy.
The data showed that the beneficial clinical effects of molgramostim were similar in patients with aPAP, regardless of their disease severity as defined by DLco%. This indicates a broad applicability of the treatment across the patient spectrum.
Furthermore, changes in DLco%, the primary endpoint in IMPALA-2, were significantly correlated with changes in measures of quality of life, patient functionality, and surfactant burden in aPAP patients. Savara's partner, TrilliumBiO, also presented data on a dried blood spot test for aPAP diagnosis.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.